Form 4: Sangamo Therapeutics CEO Sandy Macrae Reports Stock Transactions

CEO Sandy Macrae reports disposition of shares for tax withholding and acquisition of shares through RSU grants and stock options.

Summary

• Sandy Macrae, CEO of Sangamo Therapeutics, reported transactions involving the company's stock.
• On February 24, 2025, Macrae disposed of 7,488 shares at $1.00 per share to cover tax obligations related to vesting RSUs.
• On February 25, 2025, Macrae disposed of 10,663 shares at $0.9561 per share for tax withholding related to vesting RSUs.
• Also on February 25, 2025, Macrae acquired 375,000 shares through an RSU grant.
• Macrae also acquired options to purchase 1,750,000 shares of common stock at an exercise price of $0.9561 on February 25, 2025.
• The vesting of the RSU grants and stock options is subject to Macrae's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, with the grant of RSUs and stock options generally viewed positively as aligning management interests with shareholders. The tax-related sales are neutral.

Positives

• The grant of 375,000 shares via RSU and 1,750,000 stock options to the CEO indicates continued alignment of interests with shareholders.
• The vesting schedules of the RSUs and stock options incentivize long-term performance and retention of the CEO.

Negatives

• The disposition of shares to cover tax obligations, while standard, slightly reduces the CEO's direct shareholding.

Risks

• The vesting of RSUs and stock options is contingent on the CEO's continued service, creating a potential risk if the CEO were to leave the company.
• Fluctuations in the stock price could impact the value of the RSUs and stock options, potentially affecting the CEO's motivation.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options, which are contingent on continued service.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The vesting of RSUs and grant of stock options are common methods for incentivizing executives in the biotechnology industry.

Comparison to Industry Standards

• RSU and stock option grants are standard compensation practices in the biotech industry, used to align executive incentives with shareholder value.
• Vesting schedules are typically structured to encourage long-term commitment, often over a period of 2-4 years for RSUs and longer for stock options.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders: Transparency into executive compensation and alignment of interests.
• Employees: Understanding of executive incentives and potential impact on company performance.

Next Steps

• Continued monitoring of insider transactions to assess management's confidence in the company.
• Tracking the vesting of RSUs and stock options to understand the ongoing alignment of incentives.

Key Dates